Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

ProtoKinetix AAGP® Operational Update

November 6, 2019 GMT

MARIETTA, Ohio--(BUSINESS WIRE)--Nov 6, 2019--

ProtoKinetix, Incorporated ( www.protokinetix.com ) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX ) is pleased to provide the following updates regarding upcoming news in key areas.

Current projects updates are expected from the following:


Dry Eye Disease (DED) – ProtoKinetix is expecting closure of agreements for the first steps in a roll-out of a new product line development that will test AAGP® for treatments related to Dry Eye Disease. An update is expected for the 3 rd week of November.




Retinal Cell Replacement – Final phase of the work that was conducted by Dr. Kevin Gregory-Evans has been completed, the data is being compiled. An update is expected in December of this year.

Social Media:

For more Company information and to sign up for regular updates, visit our website at ProtoKinetix.com.

Please visit our new Facebook page: ProtoKinetix Facebook
Join us on Twitter @ProtoKinetix.
Join us on Linkedin: ProtoKinetix Linkedin

Our new website is expected to be live in the first quarter of 2020.

About ProtoKinetix, Incorporated

ProtoKinetix is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP®) that enhance both engraftment and protection of transplanted cells used in regenerative medicine. Due to the results achieved over the last four years of testing, the University of Alberta has begun Phase 1 human clinical trials. Additional studies will be expanded are planned to include whole organ transplantation and all therapies that are being developed globally to date; diabetes, retinal degeneration, cardiac repair and many other degenerative conditions. In addition, we are studying the potential impact on several cancer therapies.

Cautionary Note Regarding Forward-Looking Statements

The information discussed in this press release includes “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”). All statements, other than statements of historical facts, included herein concerning, among other things, planned capital expenditures, future cash flows and borrowings, pursuit of potential acquisition opportunities, our financial position, business strategy and other plans and objectives for future operations, are forward looking statements. These forward looking statements are identified by their use of terms and phrases such as “may,” “expect,” “estimate,” “project,” “plan,” “believe,” “intend,” “achievable,” “anticipate,” “will,” “continue,” “potential,” “should,” “could,” and similar terms and phrases. Although we believe that the expectations reflected in these forward looking statements are reasonable, they do involve certain assumptions, risks and uncertainties and are not (and should not be considered to be) guarantees of future performance. Among these risks are those set forth in a Form 10-K filed on March 13, 2019. It is important that each person reviewing this release understand the significant risks attendant to the operations of ProtoKinetix. ProtoKinetix disclaims any obligation to update any forward-looking statement made here.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191106005176/en/

CONTACT: Clarence E. Smith

President and Chief Executive Officer

Telephone: 304-299-5070




SOURCE: ProtoKinetix

Copyright Business Wire 2019.

PUB: 11/06/2019 09:00 AM/DISC: 11/06/2019 09:01 AM